Skip to main content
. Author manuscript; available in PMC: 2022 Aug 1.
Published in final edited form as: Lancet Haematol. 2021 Aug;8(8):e552–e561. doi: 10.1016/S2352-3026(21)00192-7

Table 1:

Baseline Characteristics

N = 50
Age 48 (18 - 64)
Race
White 30 / 50 (60%)
Black 10 / 50 (20%)
Asian 2 / 50 (4.0%)
Hispanic 1 / 50 (2.0%)
Other 7 / 50 (14%)
Gender
Female 22 / 50 (44%)
Male 28 / 50 (56%)
Diagnosis
AML 45 / 50 (90%)
MDS 4 / 50 (8.0%)
MPAL 1 / 50 (2.0%)
Cytogenetic Group
Favorable 1 / 50 (2.0%)
Diploid 25 / 50 (50%)
Other Intermediate 8 / 50 (16%)
Adverse/Complex 10 / 50 (20%)
Insufficient Mitoses 5 / 50 (10%)
ELN Risk
Favorable 16 / 46 (35%)
Intermediate 14 / 46 (30%)
Adverse 16 / 46 (35%)
IPSS-R
High 2 / 4 (50%)
Very High 2 / 4 (50%)
Baseline Bone
Marrow Blasts
AML 59 (1 – 84)
MDS 9.5 (8-18)
MPAL 82
Baseline WBC 6 (1 - 70)
Baseline Peripheral Blasts 20 (1 - 95)
Baseline Hemoglobin 8.60 (7.00 - 13.20)
Baseline Platelet Count 44 (6 - 398)
Baseline Total Bilirubin 0.40 (0.20 - 1.30)
Baseline Serum Creatinine 0.84 (0.50 - 1.39)

Median (Range); n / N (%)